Traws Pharma Statistics
Total Valuation
Traws Pharma has a market cap or net worth of $8.36 million. The enterprise value is $3.35 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Traws Pharma has 3.65 million shares outstanding. The number of shares has increased by 18.39% in one year.
| Current Share Class | 3.65M |
| Shares Outstanding | 3.65M |
| Shares Change (YoY) | +18.39% |
| Shares Change (QoQ) | -5.03% |
| Owned by Insiders (%) | 29.88% |
| Owned by Institutions (%) | 15.47% |
| Float | 1.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.54 |
| Forward PS | 35.79 |
| PB Ratio | -4.31 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.07
| Current Ratio | 1.07 |
| Quick Ratio | 0.90 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2,255.45% and return on invested capital (ROIC) is -241.25%.
| Return on Equity (ROE) | -2,255.45% |
| Return on Assets (ROA) | -83.72% |
| Return on Invested Capital (ROIC) | -241.25% |
| Return on Capital Employed (ROCE) | -4,097.62% |
| Revenue Per Employee | $12,556 |
| Profits Per Employee | -$7.82M |
| Employee Count | 18 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.73% in the last 52 weeks. The beta is 1.42, so Traws Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | -90.73% |
| 50-Day Moving Average | 4.66 |
| 200-Day Moving Average | 7.00 |
| Relative Strength Index (RSI) | 28.20 |
| Average Volume (20 Days) | 50,552 |
Short Selling Information
The latest short interest is 76,309, so 2.09% of the outstanding shares have been sold short.
| Short Interest | 76,309 |
| Short Previous Month | 172,313 |
| Short % of Shares Out | 2.09% |
| Short % of Float | 4.04% |
| Short Ratio (days to cover) | 0.58 |
Income Statement
In the last 12 months, Traws Pharma had revenue of $226,000 and -$140.79 million in losses. Loss per share was -$141.78.
| Revenue | 226,000 |
| Gross Profit | 226,000 |
| Operating Income | -24.09M |
| Pretax Income | -18.16M |
| Net Income | -140.79M |
| EBITDA | -24.08M |
| EBIT | -24.09M |
| Loss Per Share | -$141.78 |
Full Income StatementBalance Sheet
The company has $5.41 million in cash and n/a in debt, giving a net cash position of $5.41 million or $1.48 per share.
| Cash & Cash Equivalents | 5.41M |
| Total Debt | n/a |
| Net Cash | 5.41M |
| Net Cash Per Share | $1.48 |
| Equity (Book Value) | -2.03M |
| Book Value Per Share | -0.67 |
| Working Capital | 575,000 |
Full Balance SheetCash Flow
| Operating Cash Flow | -30.18M |
| Capital Expenditures | n/a |
| Free Cash Flow | -30.18M |
| FCF Per Share | -$8.27 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -10,661.06% |
| Pretax Margin | -62,294.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |